Antifungal Safety with Apremilast
Most antifungal agents are safe to use with apremilast, with the critical exception of azole antifungals (fluconazole, itraconazole, voriconazole, posaconazole) which do not have direct drug interactions with apremilast but require caution, while echinocandins (caspofungin, micafungin, anidulafungin) and amphotericin B formulations are the safest choices for systemic fungal infections in patients on apremilast.
Key Drug Interaction Principle
The FDA label for apremilast specifically warns against strong CYP450 enzyme inducers (rifampin, phenobarbital, carbamazepine, phenytoin), which reduce apremilast exposure and efficacy 1. Importantly, azole antifungals are CYP450 inhibitors, not inducers, so they do not reduce apremilast levels—however, this creates a different consideration.
Safe Antifungal Options by Class
Safest: Echinocandins (First Choice for Systemic Infections)
- Caspofungin, micafungin, anidulafungin have no CYP450-mediated interactions
- Recommended as first-line for candidemia and invasive candidiasis 2, 3
- No dose adjustment needed with apremilast
- This is your go-to class for serious fungal infections in apremilast patients
Safe: Amphotericin B Formulations
- Liposomal amphotericin B (LFAmB) and amphotericin B deoxycholate have no drug interactions with apremilast
- Alternative for invasive candidiasis when echinocandins unavailable 4
- Monitor for nephrotoxicity (unrelated to apremilast interaction)
Generally Safe: Azole Antifungals (Use with Awareness)
- Fluconazole, itraconazole, voriconazole are CYP3A4 inhibitors, not inducers
- They will not reduce apremilast efficacy (the main FDA concern)
- Theoretical concern: Could potentially increase apremilast levels, though this is not documented in the FDA label
- Widely used for candidiasis, onychomycosis, and other fungal infections 4, 5
- Practical approach: Use standard azole dosing; monitor for apremilast-related adverse effects (diarrhea, nausea, headache) which might be amplified if levels increase
Safe: Topical Antifungals
- Topical azoles, terbinafine, ciclopirox, amorolfine have minimal systemic absorption
- No clinically significant interactions expected 6
- Preferred for superficial fungal infections (dermatophytosis, onychomycosis, candidiasis)
Safe: Terbinafine (Oral)
- Minimal drug interaction profile compared to azoles 7
- Does not significantly affect CYP450 enzymes
- Preferred oral agent for dermatophyte onychomycosis 5
Clinical Algorithm
For superficial fungal infections (tinea, onychomycosis, mucocutaneous candidiasis):
- Use topical antifungals as first-line (no interaction concerns)
- If oral therapy needed: Terbinafine for dermatophytes, fluconazole for Candida
- Monitor for increased GI side effects (diarrhea, nausea) if using oral azoles
For invasive/systemic fungal infections:
- Echinocandins (caspofungin, micafungin, anidulafungin) are first-line—no interaction
- Amphotericin B formulations as alternative—no interaction
- Azoles (fluconazole, voriconazole) can be used for step-down therapy or specific indications (C. krusei, CNS infections) 2, 3
Critical Pitfalls to Avoid
- Do NOT confuse azoles with rifampin: Azoles inhibit CYP450 (potentially increasing apremilast), while rifampin induces CYP450 (definitely decreasing apremilast). Only the latter is contraindicated 1
- Do NOT avoid azoles unnecessarily: They remain guideline-recommended for many fungal infections and can be used with apremilast
- Monitor for additive GI effects: Both apremilast and azoles can cause nausea/diarrhea; consider this when selecting therapy 1
- Topical therapy preferred when possible: Minimizes any theoretical systemic interaction risk 6
Species-Specific Considerations
For Candida infections requiring systemic therapy in apremilast patients: